3 rare disease campaigns that conquered challenges around marketing these conditions
We analyze three winning rare disease campaigns that illustrate the challenges and opportunities that come with operating in such a difficult realm.
Most recent articles by Laura Entis
Why the dance between manufacturers and PBMs continues
States have targeted co-pay accumulators, claiming they run up costs for patients who need expensive specialty drugs. Here’s why their legislation hasn’t yet had the intended impact.
ZDoggMD is redefining the scope and tone of physician influence on social media
Dr. Zubin Damania is known across the social media universe as ZDoggMD.
Heart meds, digital therapeutics highlight day three of JP Morgan ‘19
Day three at the JP Morgan Healthcare Conference included insights from executives at Amarin and Pear Therapeutics.
Drug prices, digital partnerships, diversity take center stage on day two of JP Morgan ‘19
Meanwhile, an upstart conference made its mark nearby.
Day one at JP Morgan ‘19: Mega-deals, accessibility, and price gouging (by hotels)
Deals, access and pricing, and the cost of attending one of healthcare’s biggest events ruled day one buzz at the conference.
Co-pay accumulators: A force to be reckoned with in 2019
Experts predict the controversial tactic will be deployed far more widely this year, significantly impacting manufacturers — and, whether or not they realize it yet, patients.
How to lower drug prices in the U.S.? Lots of suggestions, few viable solutions
A panel representing pharma, government payer, and policy analyst presented three potential big-picture goals to strive for.
Five things for pharma marketers to know: Tuesday, October 30, 2018
The rise and fall of Dr. Piero Anversa; Database of retracted scientific papers posted; Why PhRMA is worried about a “blue wave.”
Five things for pharma marketers to know: Monday, October 29, 2018
2018 Health Influencer 50; Have we reached peak CBD?; Justice Department reaches $25 million settlement with Abbott, AbbVie.
